Hansa Biopharma AB (publ)

BMV:HNSA N Stock Report

Market Cap: Mex$4.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hansa Biopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Søren Tulstrup

Chief executive officer

SEK 26.5m

Total compensation

CEO salary percentage28.6%
CEO tenure5.3yrs
CEO ownershipn/a
Management average tenure4.1yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Søren Tulstrup's remuneration changed compared to Hansa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-SEK 678m

Dec 31 2022SEK 26mSEK 8m

-SEK 611m

Sep 30 2022n/an/a

-SEK 626m

Jun 30 2022n/an/a

-SEK 620m

Mar 31 2022n/an/a

-SEK 583m

Dec 31 2021SEK 26mSEK 7m

-SEK 548m

Sep 30 2021n/an/a

-SEK 491m

Jun 30 2021n/an/a

-SEK 465m

Mar 31 2021n/an/a

-SEK 431m

Dec 31 2020SEK 21mSEK 6m

-SEK 421m

Sep 30 2020n/an/a

-SEK 426m

Jun 30 2020n/an/a

-SEK 398m

Mar 31 2020n/an/a

-SEK 381m

Dec 31 2019SEK 11mSEK 5m

-SEK 360m

Sep 30 2019n/an/a

-SEK 330m

Jun 30 2019n/an/a

-SEK 298m

Mar 31 2019n/an/a

-SEK 274m

Dec 31 2018SEK 8mSEK 4m

-SEK 248m

Compensation vs Market: Søren's total compensation ($USD2.45M) is above average for companies of similar size in the MX market ($USD532.66K).

Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.

CEO

Søren Tulstrup (58 yo)

5.3yrs

Tenure

SEK 26,481,000

Compensation

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Leadership Team

NamePositionTenureCompensationOwnership
Søren Tulstrup
President & CEO5.3yrsSEK 26.48mno data
Donato Spota
CFO & Senior VP4.1yrsno data0.011%
MX$ 428.1k
Christian Kjellman
Senior VP15.4yrsno data0.012%
MX$ 468.9k
Eva-Maria Joed
Vice President of Finance & Administration4.1yrsno datano data
Klaus Sindahl
VP & Head of Investor Relationsno datano datano data
Anne Lanner
Senior VP & Chief Human Resources Officer4.4yrsno datano data
Emanuel Björne
VP & Head of Business Developmentno datano datano data
Lena Winstedt
Head of Scienceno datano datano data
Vincenza Nigro
VP & Head of Medical Affairsno datano datano data
Achim Kaufhold
Senior VP & Chief Medical Officer3yrsno datano data
Magnus Korsgren
VP & Head of Research and Development2.2yrsno datano data
Matthew Shaulis
Chief Commercial Officer & President of the U.S. Affiliateless than a yearno datano data

4.1yrs

Average Tenure

54yo

Average Age

Experienced Management: HNSA N's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anders Pedersen
Independent Director5.1yrsSEK 386.00k0.0048%
MX$ 188.7k
Mats Blom
Independent Director4.1yrsSEK 493.00k0.0019%
MX$ 75.6k
Peter Nicklin
Independent Chairman of the Board1yrSEK 525.00k0.028%
MX$ 1.1m
Eva Nilsagard
Independent Director4.1yrsSEK 591.00k0.0057%
MX$ 226.3k
Hilary Malone
Independent Director2.1yrsSEK 698.00kno data
Andreas Eggert
Independent Director5.1yrsSEK 578.00k0.010%
MX$ 415.1k
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantationno datano datano data
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantationno datano datano data
Christophe Legendre
Member of European Medical Advisory Board in Transplantationno datano datano data
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantationno datano datano data
Robert Montgomery
Member of US Medical Advisory Board in Transplantationno datano datano data

4.1yrs

Average Tenure

58.5yo

Average Age

Experienced Board: HNSA N's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/13 05:48
End of Day Share Price 2023/03/16 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansa Biopharma AB (publ) is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Christian LeeABG Sundal Collier Sponsored
Madhu KumarB. Riley Securities, Inc.